Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 -0.68%19 5-Year Yield-on-Cost % is 0.43 as of Aug. 19, 2026, which is 65% above its 10-year median of 0.26. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 508 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 82.48% on this metric.
Pet Pharm Biotech Co's yield on cost for the quarter that ended in Dec. 2025 was 0.43.
The historical rank and industry rank for Pet Pharm Biotech Co's 5-Year Yield-on-Cost % or its related term are showing as below:
ROCO:7762'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.13 Med: 0.26 Max: 0.48
Current: 0.43
During the past 4 years, Pet Pharm Biotech Co's highest Yield on Cost was 0.48. The lowest was 0.13. And the median was 0.26.
ROCO:7762's 5-Year Yield-on-Cost % is ranked worse than 82.48% of 508
companies
in the Drug Manufacturers industry
Industry Median: 2.315
vs ROCO:7762: 0.43
Pet Pharm Biotech Co (ROCO:7762) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Pet Pharm Biotech Co 5-Year Yield-on-Cost % Related Terms
ROCO:7762 vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's 5-Year Yield-on-Cost % falls into.
Pet Pharm Biotech Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Pet Pharm Biotech Co (ROCO:7762) has a 5-Year Yield-on-Cost % of 0.43 as of Aug. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pet Pharm Biotech Co and its competitors. This is 65% above median its historical median of 0.26. Over the past decade, Pet Pharm Biotech Co's 5-Year Yield-on-Cost % has ranged from 0.13 to 0.48. According to the industry distribution chart, Pet Pharm Biotech Co ranks #419 out of 508 companies in the Drug Manufacturers industry, placing it in the top 82.5%.
Is Pet Pharm Biotech Co's 5-Year Yield-on-Cost % too high?
Pet Pharm Biotech Co's current 5-Year Yield-on-Cost % of 0.43 is 65% above median its 10-year median of 0.26. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.48. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. Pet Pharm Biotech Co's value of 0.43 is 81.4% below this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #419 out of 508 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #419 out of 508 companies for 5-Year Yield-on-Cost %. This places Pet Pharm Biotech Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.32. Pet Pharm Biotech Co's value of 0.43 is 81.4% below this benchmark. Historically, Pet Pharm Biotech Co's own 5-Year Yield-on-Cost % has ranged from 0.13 to 0.48 over the past decade. While the company's 10-year median is 0.26 vs. the industry median of 2.32, Pet Pharm Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current 5-Year Yield-on-Cost % of 0.43 is 81.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current 5-Year Yield-on-Cost % is 0.43, which is 65% above median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current 5-Year Yield-on-Cost % of 0.43. The current 5-Year Yield-on-Cost % is 0.43, which is 65% above median its 10-year median of 0.26 and 81.4% below the Drug Manufacturers industry median of 2.32. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current 5-Year Yield-on-Cost % is 0.43 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score
Get the complete analysis for ROCO:7762
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
